OBJECTIVES: The aim of this study was to examine the associations between depressive symptoms and mental stress-induced myocardial ischemia (MSIMI) in patients with coronary heart disease (CHD). METHODS: Adult patients with documented CHD were recruited for baseline mental stress and exercise stress screening testing as a part of the enrollment process of the Responses of Myocardial Ischemia to Escitalopram Treatment trial. Patients were administered the Beck Depression Inventory II and the Center for Epidemiologic Studies Depression Scale. After a 24-48-hour β-blocker withdrawal, participants completed three mental stress tests followed by a treadmill exercise test. Ischemia was defined as a) any development or worsening of any wall motion abnormality and b) reduction of left ventricular ejection fraction at least 8% by transthoracic echocardiography and/or ischemic ST-segment change by electrocardiography during stress testing. MSIMI was considered present when ischemia occurred in at least one mental test. Data were analyzed using logistic regression adjusting for age, sex, and resting left ventricular ejection fraction. RESULTS: One hundred twenty-five (44.2%) of 283 patients were found to have MSIMI, and 93 (32.9%) had ESIMI. Unadjusted analysis showed that Beck Depression Inventory II scores were positively associated with the probability of MSIMI (odds ratio = 0.1.30: 95% confidence interval = 1.06-1.60, p = .013) and number of MSIMI-positive tasks (all p < .005). These associations were still significant after adjustment for covariates (p values <.05). CONCLUSIONS: In patients with CHD, depressive symptoms were associated with a higher probability of MSIMI. These observations may enhance our understanding of the mechanisms contributing to the association of depressive symptoms to future cardiovascular events. Trial Registration Clinicaltrials.gov identifier: NCT00574847.
OBJECTIVES: The aim of this study was to examine the associations between depressive symptoms and mental stress-induced myocardial ischemia (MSIMI) in patients with coronary heart disease (CHD). METHODS: Adult patients with documented CHD were recruited for baseline mental stress and exercise stress screening testing as a part of the enrollment process of the Responses of Myocardial Ischemia to Escitalopram Treatment trial. Patients were administered the Beck Depression Inventory II and the Center for Epidemiologic Studies Depression Scale. After a 24-48-hour β-blocker withdrawal, participants completed three mental stress tests followed by a treadmill exercise test. Ischemia was defined as a) any development or worsening of any wall motion abnormality and b) reduction of left ventricular ejection fraction at least 8% by transthoracic echocardiography and/or ischemic ST-segment change by electrocardiography during stress testing. MSIMI was considered present when ischemia occurred in at least one mental test. Data were analyzed using logistic regression adjusting for age, sex, and resting left ventricular ejection fraction. RESULTS: One hundred twenty-five (44.2%) of 283 patients were found to have MSIMI, and 93 (32.9%) had ESIMI. Unadjusted analysis showed that Beck Depression Inventory II scores were positively associated with the probability of MSIMI (odds ratio = 0.1.30: 95% confidence interval = 1.06-1.60, p = .013) and number of MSIMI-positive tasks (all p < .005). These associations were still significant after adjustment for covariates (p values <.05). CONCLUSIONS: In patients with CHD, depressive symptoms were associated with a higher probability of MSIMI. These observations may enhance our understanding of the mechanisms contributing to the association of depressive symptoms to future cardiovascular events. Trial Registration Clinicaltrials.gov identifier: NCT00574847.
Authors: K Yoshida; T Utsunomiya; T Morooka; M Yazawa; K Kido; T Ogawa; T Ryu; T Ogata; S Tsuji; T Tokushima; S Matsuo Journal: Int J Cardiol Date: 1999-07-31 Impact factor: 4.164
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Wei Jiang; Zainab Samad; Stephen Boyle; Richard C Becker; Redford Williams; Cynthia Kuhn; Thomas L Ortel; Joseph Rogers; Maragatha Kuchibhatla; Christopher O'Connor; Eric J Velazquez Journal: J Am Coll Cardiol Date: 2013-02-19 Impact factor: 24.094
Authors: J Douglas Bremner; Carolina Campanella; Zehra Khan; Majid Shah; Muhammad Hammadah; Kobina Wilmot; Ibhar Al Mheid; Bruno B Lima; Ernest V Garcia; Jonathon Nye; Laura Ward; Michael H Kutner; Paolo Raggi; Brad D Pearce; Amit J Shah; Arshed A Quyyumi; Viola Vaccarino Journal: Psychosom Med Date: 2018 Jul/Aug Impact factor: 4.312
Authors: Pratik Pimple; Muhammad Hammadah; Kobina Wilmot; Ronnie Ramadan; Ibhar Al Mheid; Oleksiy Levantsevych; Samaah Sullivan; Bruno B Lima; Jeong Hwan Kim; Ernest V Garcia; Jonathon Nye; Amit J Shah; Laura Ward; Paolo Raggi; J Douglas Bremner; John Hanfelt; Tené T Lewis; Arshed A Quyyumi; Viola Vaccarino Journal: Psychosom Med Date: 2019-05 Impact factor: 4.312
Authors: Julia L Sun; Stephen H Boyle; Zainab Samad; Michael A Babyak; Jennifer L Wilson; Cynthia Kuhn; Richard C Becker; Thomas L Ortel; Redford B Williams; Joseph G Rogers; Christopher M O'Connor; Eric J Velazquez; Wei Jiang Journal: Eur J Prev Cardiol Date: 2017-01-09 Impact factor: 7.804
Authors: Jacob P Feigal; Stephen H Boyle; Zainab Samad; Eric J Velazquez; Jennifer L Wilson; Richard C Becker; Redford B Williams; Cynthia M Kuhn; Thomas L Ortel; Joseph G Rogers; Christopher M O'Connor; Wei Jiang Journal: J Psychosom Res Date: 2016-11-29 Impact factor: 3.006
Authors: Stephen H Boyle; Wayne R Matson; Eric J Velazquez; Zainab Samad; Redford B Williams; Swati Sharma; Beena Thomas; Jennifer L Wilson; Christopher O'Connor; Wei Jiang Journal: Metabolomics Date: 2015-06-01 Impact factor: 4.290
Authors: Izraelle I McKinnon; Amit J Shah; Bruno Lima; Kasra Moazzami; An Young; Samaah Sullivan; Zakaria Almuwaqqat; Mariana Garcia; Lisa Elon; J Douglas Bremner; Paolo Raggi; Arshed A Quyyumi; Viola Vaccarino; Tené T Lewis Journal: Psychosom Med Date: 2021-06-01 Impact factor: 3.864